Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BioShin

Request full access

Develop and sell a series of Biohaven pharmaceutical products in Asia

Pudong, ChinaFounded 2018Biotech & Life Sciences

About BioShin

BioShin is a Shanghai-based biopharmaceutical company operating as an Asia-Pacific subsidiary of the U.S. firm Biohaven Pharmaceutical Holding Company Ltd. Established in 2018, BioShin's primary objective is to develop and commercialize Biohaven's late-stage clinical portfolio for patients in the Asia-Pacific region, excluding Japan. The company focuses on addressing the significant unmet medical needs in neurologic and neuropsychiatric diseases, such as migraine, which affects an estimated 90 million individuals in China alone.

The formation of BioShin was a strategic move by Biohaven to tap into the burgeoning Asia-Pacific healthcare market, driven by regulatory changes and a growing patient population. Initially led by Donnie McGrath, M.D., who transitioned from his role at Biohaven, the company appointed Karl Lintel as CEO in September 2020. Lintel brought extensive experience from his previous roles as President and General Manager of Bristol-Myers Squibb in China. The broader management team comprises veterans from major pharmaceutical companies like Pfizer, Sanofi, and Novartis, highlighting a deep well of international and regional expertise.

BioShin's business model centers on licensing and advancing Biohaven's drug pipeline. The company secured a significant milestone in September 2020 by closing a $60 million Series A funding round led by OrbiMed, with participation from other notable healthcare investors. This capital infusion was earmarked to fund the build-out of its operations in China and to advance clinical trials for key product candidates. The company's core activity is conducting clinical trials to gain regulatory approval for these drugs in markets like China and South Korea. A primary product in its portfolio is rimegepant (marketed as Nurtec ODT in the U.S.), an orally administered treatment for acute migraine. BioShin has been conducting a Phase 3 trial for rimegepant in China and South Korea. The company is also advancing trials for troriluzole, a treatment for the rare genetic movement disorder Spinocerebellar Ataxia (SCA).

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
22.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Sep 2020 $60M $240M Suvretta Capital Management · Citadel · Cormorant Asset Management · OrbiMed —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

BioShin website traffic

Latest recorded traffic for BioShin is 50 monthly website visits, down 70.6% over the last three months.

Latest monthly visits50 3-month web change-70.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

BioShin in the Pudong ecosystem

Live from Dealroom

The BioShin office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Pudong HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BioShin on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BioShin’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.